Assessment of clinical significance of serum uric acid, serum bilirubin and serum creatinine in patients with breast lump

Shoranki Pardhan, Anuradha Chaudhary, Rahul Shivhare, Sonveer Gautam


Background: Breast cancer is the most common cancer in females, approximately a quarter of all cancers. Several tumor markers are being studied now a days like α feto protein, carcinoembryonic antigen, and human chorionic gonadotropin but, the cost of these analytical methods is very high. This study is directed to assess prognostic value of serum uric acid, serum bilirubin and serum creatinine in breast lump cases. And to compare variation in benign and malignant breast lumps in relation to serum uric acid, serum bilirubin and serum creatinine values.

Methods: Observational and prospective study conducted in Hamidia Hospital, Bhopal from November 2018-July 2020 included 100 patients. 50 patients were having benign breast lumps and other 50 patients malignant. Categorization of the patients done on the basis of histopathological examination. Autoanalyzer was used for estimation of serum uric acid, serum bilirubin and serum creatinine.

Results: High serum uric acid level may anticipate poor prognosis in carcinoma breast, and it may perform a promising role in the management of the same. The level of serum bilirubin was slightly more or within normal range. The level of serum creatinine was within normal range in absence of any renal impairment by other etiology.

Conclusions: The evaluation of serum uric acid and serum bilirubin may be useful for predicting prognosis in females with malignant breast lump and can provide help in making diagnosis during the initial assessment of the patient presenting with breast lump.


Biochemical parameters, Breast cancer, Prognosis of carcinoma breast, Anti-oxidant property

Full Text:



Caleffi M, Filho DD, Borghetti K, Graudenz M, Littrup PJ, Freeman-Gibb LA, et al. Cryoablation of benign breast tumors: evolution of technique and technology. Breast. 2004;13:397-407.

Murillo Ortiz B, Botello Hernandez D, Ramirez Mateos C, Reynaga Garcia FJ. Benign breast diseases: clinical, radiological and pathological correlation. Ginecol Obstet Mex. 2002;70:613-8.

Heuser L, Spratt JS, Polk HC Jr. Growth rates of primary breast cancers. Cancer. 1979;43:1888-94.

Gupta A, Shridhar K, Dhillon PK. A review of breast cancer awareness among women in India: cancer literate or awareness deficit? Eur J Cancer. 2015;51:2058-66.

Kaarthigeyan K. Cervical cancer in India and HPV vaccination. Indian J Med Paediatr Oncol. 2012;33:7-12.

Ferlay J, Soerjomataram I, Dikshit R. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359-86.

Chhabra RJ, Mangukiya k, Sharma N, Sharma R. Estimation of Serum Uric Acid and Bilirubin in Breast Cancer. Sch Acad J Pharm. 2015;4(7):337-9.

Kang D. Oxidative stress, DNA damage and breast cancer. AACN Clin issues. 2002;540-9.

Krishna Veni G, Bhaskar Rao D, Muni Kumar D, Usha B, Murli Krishna V, Raghava Roa T. Clinical evaluation of oxidative stress in women with breast cancer. Rec Res Sci Tech. 2011;3:55-8.

Sedlak Thomas W, Synder SH, Bilirubin benefits, cellular protection by a biliverdin reductase antioxidant cycle. Paediatrics. 2004;113:1776-82.

Kepitulnik J. Bilirubin. An endogenous products of Heme degradation with both cytotoxic and cyto protective properties. Mol Pharmacol. 2004;66:773-9.

Fisher SM, Floyd RA, Cope-land ES. Workshop grants. National Institute of Health. Oxy radicals in carcinogenesis a chemical pathology study section workshop. Cancer Res. 1983;43:5631-4.

Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78(11):6858-62.

Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235(4792):1043-6.

Halliwell B. Albumin—an important extracellular antioxidant? Biochem Pharmacol. 1988;37(4):569-71.

Ko WF, Helzlsouer KJ, Comstock GW. Serum albumin, bilirubin, and uric acid and the anatomic site-specific incidence of colon cancer. J Natl Cancer Inst. 1994;86(24):1874-5.

Ching S, Ingram D, Hahnel R, Beilby J, Rossi E. Serum levels of micronutrients, antioxidants and total antioxidant status predict risk of breast cancer in a case control study. J Nutr. 2002;132(2):303-6.

Zucker SD, Horn PS, Sherman KE. Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology. 2004;40(4):827-35.

Lin H, Lin HX, Ge N, Wang HZ, Sun R, Hu WH. Plasma uric acid and tumor volume are highly predictive of outcome in nasopharyngeal carcinoma patients receiving intensity modulated radiotherapy. Radiat Oncol. 2013;8:121.

Dziaman T, Banaszkiewicz Z, Roszkowski K, Gackowski D, Wisniewska E, Rozalski R, et al. 8-Oxo-7,8-dihydroguanine and uric acid as efficient predictors of survival in colon cancer patients. Int J Cancer 2014;134(2):376-83.

Liu X, Meng QH, Ye Y, Hildebrandt MA, Gu J, Wu X. Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer. Carcinogenesis. 2015;36(2):243-8.

Shin HS, Lee HR, Lee DC, Shim JY, Cho KH, Suh SY. Uric acid as a prognostic factor for survival time: a prospective cohort study of terminally ill cancer patients. J Pain Symptom Manage. 2006;31(6):493-501.

Haas M, Heinemann V, Kullmann F, Laubender RP, Klose C, Bruns CJ, et al. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol. 2013;139(4):681-9.

Stotz M, Szkandera J, Seidel J, Stojakovic T, Samonigg H, Reitz D, et al. Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients. PLoS One. 2014;9(8):104730.

Gao C, Fang L, Li JT, Zhao HC. Significance and prognostic value of increased serum direct bilirubin level for lymph node metastasis in Chinese rectal cancer patients. World J Gastroenterol. 2016;22(8):2576-84.

Yan S, Zhang P, Xu W, Liu Y, Wang B, Jiang T, Hua C, Wang X, Xu D, Sun B. Serum uric acid increases risk of cancer incidence and mortality: a systematic review and meta-analysis. Mediators Inflamm. 2015;764250.

Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012;1(1):16.

Horsfall LJ, Rait G, Walters K, Swallow DM, Pereira SP, Nazareth I, Petersen I. Serum bilirubin and risk of respiratory disease and death. JAMA. 2011;305(7):691-7.

Novotný L, Vítek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood). 2003;228(5):568-71.

Alexandre J, Bleuzen P, Bonneterre J, Sutherland W, Misset JL, Guastalla J, et al. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol. 2000;18(3):562-73.